We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment and Response |

BRAF V600E Mutation and Papillary Thyroid Cancer—In Reply

Anne R. Cappola, MD, ScM1; Susan J. Mandel, MD, MPH1
[+] Author Affiliations
1Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
JAMA. 2013;310(5):535-536. doi:10.1001/jama.2013.8595.
Text Size: A A A
Published online


In Reply We agree with Dr Xing that the analyses presented by Xing et al support an important biological role for BRAF V600E in promoting aggressive tumor behaviors. We disagree with Xing’s interpretation of the multivariable mortality analyses that included BRAF V600E status and PTC tumor behaviors (extrathyroidal invasion, lymph node metastases, and distant metastases) as predictors.

What these multivariable analyses showed was that when the BRAF V600E test result was examined together with aggressive tumor behaviors, BRAF V600E status was no longer independently associated with mortality. This multivariable model replicates the question confronting the clinician: what does knowledge of BRAF V600E status add to existing clinical staging? As we discussed in our Editorial, the analyses by Xing et al suggest that BRAF V600E testing does not contribute to the predictive value for PTC-related mortality beyond the information gleaned about aggressive tumor characteristics reported by a pathologist or radiological evaluation.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




August 7, 2013
Mingzhao Xing, MD, PhD
1Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA. 2013;310(5):535. doi:10.1001/jama.2013.8592.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Related Collections